BIIB:NGS-Biogen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 340.72

Change

-2.91 (-0.85)%

Market Cap

USD 68.64B

Volume

0.95M

Yahoo Analyst Target

USD 389.12 (14.21%)

STA Analyst Target

USD 372.42 (9.30%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-08-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-0.50 (-0.26%)

USD 126.39B
GILD Gilead Sciences Inc.

-2.47 (-3.19%)

USD 97.02B
CELG Celgene Corporation

-3.44 (-3.71%)

USD 62.79B
SHPG Shire plc

-0.80 (-0.47%)

USD 51.31B
VRTX Vertex Pharmaceuticals Incorpo..

-2.93 (-1.67%)

USD 44.21B
REGN Regeneron Pharmaceuticals Inc.

-4.36 (-1.19%)

USD 39.10B
ALXN Alexion Pharmaceuticals Inc.

-4.36 (-3.64%)

USD 25.70B
BMRN BioMarin Pharmaceutical Inc.

-1.33 (-1.29%)

USD 18.08B
INCY Incyte Corporation

+0.42 (+0.63%)

USD 14.22B
GRFS Grifols S.A.

-0.71 (-3.43%)

USD 13.66B

ETFs Containing BIIB

IBB iShares Nasdaq Biotechnol.. 8.50 % 0.47 %

-1.83 (-1.56%)

USD 9.18B
BIB ProShares Ultra Nasdaq Bi.. 6.91 % 0.95 %

-2.33 (-3.59%)

USD 0.34B
UBIO Proshares UltraPro Nasdaq.. 6.25 % 0.95 %

-2.02 (-5.08%)

USD 0.03B
BBH VanEck Vectors Biotech ET.. 5.79 % 0.35 %

-1.92 (-1.48%)

USD 0.45B
PBE Invesco Dynamic Biotech &.. 5.10 % 0.59 %

-0.95 (-1.64%)

USD 0.28B
LNGR Global X Longevity Themat.. 3.47 % 0.52 %

-0.37 (-1.75%)

N/A
CACG ClearBridge All Cap Growt.. 3.39 % 0.53 %

-0.51 (-1.65%)

USD 0.06B
MOAT VanEck Vectors Morningsta.. 2.76 % 0.48 %

-0.07 (-0.15%)

USD 1.50B
CLRG IQ Chaikin U.S. Large Cap.. 1.83 % 0.25 %

-0.22 (-0.85%)

USD 0.37B
QQXT First Trust NASDAQ-100 Ex.. 1.70 % 0.60 %

-0.74 (-1.42%)

USD 0.09B
FLAG Exchange Traded Concepts .. 1.11 % 1.61 %

-0.63 (-1.46%)

USD 0.02B
QQEW First Trust NASDAQ-100 Eq.. 1.10 % 0.60 %

-0.79 (-1.26%)

USD 0.57B
FLUS:CA Franklin LibertyQT U.S. E.. 1.09 % 0.28 %

N/A

CAD 0.23B
OEW Invesco S&P 100 Equal Wei.. 1.08 % 0.40 %

N/A

USD 3.39M
KRMA Global X Conscious Compan.. 0.87 % 0.43 %

-0.11 (-0.52%)

N/A
TERM EquityCompass Tactical Ri.. 0.73 % 0.65 %

-0.13 (-0.59%)

USD 0.06B
ERM EquityCompass Risk Manage.. 0.73 % 0.65 %

-0.21 (-0.92%)

USD 0.03B
SIZ AGFiQ U.S. Market Neutral.. 0.53 % 0.94 %

N/A

USD 2.04M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.95% 63% D 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.95% 63% D 60% D-
Trailing 12 Months  
Capital Gain 18.34% 61% D- 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.34% 61% D- 61% D-
Trailing 5 Years  
Capital Gain 64.97% 67% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.97% 67% D+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 4.55% 47% F 44% F
Dividend Return 4.55% 47% F 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.95% 86% B 59% F
Risk Adjusted Return 20.73% 55% F 38% F
Market Capitalization 69.21B 100% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 5% F 23% F
Price/Book Ratio 5.71 34% F 21% F
Price / Cash Flow Ratio 3.66 7% F 32% F
Price/Free Cash Flow Ratio 15.44 6% F 34% F
Management Effectiveness  
Return on Equity 23.20% 87% B+ 86% B
Return on Invested Capital 30.79% 91% A- 92% A-
Return on Assets 12.54% 96% A 92% A-
Debt to Equity Ratio 49.00% 28% F 47% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

BIIB:NGS-Biogen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 340.72

Change

-2.91 (-0.85)%

Market Cap

USD 68.64B

Volume

0.95M

Yahoo Analyst Target

USD 389.12 (14.21%)

STA Analyst Target

USD 372.42 (9.30%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-08-15